Navigation Links
SyntheMed Completes $2.8 Million Equity Financing
Date:9/3/2007

ISELIN, N.J., Aug. 14 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), today announced that it has completed the initial closing of a private placement in which it received $2.8 million in gross proceeds. Robert P. Hickey, the Company's President and CEO, stated, "The proceeds of this financing will help fund the US launch of REPEL-CV(R) Adhesion Barrier planned for the fourth quarter of this year."

At the closing, the Company issued and sold 2.8 million shares of Common Stock at $1.00 per share to a consortium of accredited overseas investors. The Company has authorized the sale of an additional 3.2 million shares in the private placement on the same terms. The Company has agreed to file a registration statement with the SEC covering the resale of the privately-placed shares within thirty days following final closing of the placement, which is anticipated to occur on or before August 31, 2007.

The securities offered in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, including statements regarding indications of the timing or ability to achieve regulatory approval and market launch for REPEL-CV or the potential market size for REPEL-CV, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future re
'/>"/>

SOURCE SyntheMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology news :

1. Worlds largest rainforest drying experiment completes first phase
2. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
3. Sandia completes depleted uranium study
4. LIAI completes worlds most comprehensive analysis on influenza virus data
5. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
6. UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders
7. Six million Africans face famine because of locusts, drought
8. Retrovirus struck ancestors of chimpanzees and gorillas millions of years ago, but did not affect ancestral humans
9. Evidence of 600-million-year old fungi-algae symbiosis discovered in marine fossils
10. $5.1 billion would save 6 million children
11. Health costs soar as 60 million Americans classed as obese

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...e of butterfly wings has inspired a 3.2m, three-ye...ation in the fields of security, energy and the en...nal technology company QinetiQ have just signed a ... based on groundbreaking physical sciences researc...ists from the University of Exeter and QinetiQ wil...
(Date:11/9/2009)...rlands, November 09, 2009 / b3c newswire / - To...and Seventh Wave, an American organization for con...companies have signed a letter of intent with rega...els TIM. The letter of intent proposes a collabora...tems for commercialization in North America. The T...
(Date:11/9/2009)...cientists and industry leaders from around the wor... AACR-NCI-EORTC Molecular Targets and Cancer Thera...re groundbreaking information on important cancer ...x disease and to treat it effectively we need a gr...ce at the molecular level," said Lewis Cantley, Ph...
Breaking Biology News(10 mins):£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Take A Swing Against Breast Cancer 21 51913 1Take A Swing Against Breast Cancer 21 51913 2ANDRES F ALONSO ESQ a Partner in the Law Firm of PARKER WAICHMAN ALONSO LLP Was Appointed Co Lead Counsel to the Plaintiffs Steering Committee in 51908 1ANDRES F ALONSO ESQ a Partner in the Law Firm of PARKER WAICHMAN ALONSO LLP Was Appointed Co Lead Counsel to the Plaintiffs Steering Committee in 51908 2Mettler Toledo International Inc to Host Second Quarter 2009 Earnings Conference Call 51904 1
...NY, October 30, 2008 Bayhill Therapeutics, Inc., ...seases, and the Juvenile Diabetes Research Foundat... 1 diabetes research, today announced a partnershi...inical trial of BHT-3021, a DNA vaccine to reverse..., BHT-3021 is an antigen-specific immunotherapeut...
...raits that we look for typically include a sense o...isma. However, a recent study suggests that it is ...cation skills that determine who is chosen as lead...at there is a gender bias when selecting leaders; ...end on the specific situation that a group finds i...
...rs at Georgetown University Medical Center have di...become resistant to tamoxifen, the world,s largest...ug. They say the findings could provide a way to i...ng from the drug, allowing doctors to try another ...f the journal Cancer Research, the researchers s...
Other Biology News:Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration 2Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration 3Gender biases in leadership selection during competitions within and between groups 2Gender biases in leadership selection during competitions within and between groups 3'New' estrogen receptor found to be key player in tamoxifen resistance 2'New' estrogen receptor found to be key player in tamoxifen resistance 3
(Date:11/9/2009)...wswire-USNewswire/ -- The Appignani Bioethics Cent..., held a panel discussion today at the National Pr...ogies in biomedical sciences and climate change. T...w Light, both of the Center for American Progress,...cal angles. ,, A video of the event will be ma...
(Date:11/9/2009)...Newswire-Asia/ -- The pharma and biotech sectors a...panies are facing significant,pressure to change w..., calls for,lower prices and a greater regulatory ...al crisis have made the work of creating new drugs...e being forced to globalize their R&D,operatio...
(Date:11/9/2009)...PRNewswire/ -- Following the provision of clinical...istration (FDA), privately,owned UK company Daval ...nal.com ) has been informed that its innovative,an...an Orphan-Drug,designation for the treatment of Am... also known as Lou Gehrig,s disease, is the most c...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- BioSpecifics Technologies...ny developing first-in-class collagenase-based pro...he third quarter ended September 30, 2009. ,, ...s year, the FDA,s Arthritis Advisory Committee una...val of XIAFLEX(TM) for the treatment of Dupuytren,...
Breaking Biology Technology:Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club 2Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club 3Pharma and Biotech Leaders to Converge in Shanghai 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6
...n of the Board -, MADISON, N.J., April 24 Wyeth ...obert Essner, 60, has decided to retire,from the C...d the position,of Chairman since January 2003 and ...1 to 2007. The Company,s Board of Directors has el... Executive Officer, to the,additional position of ...
...Inc.,(Nasdaq: HOLX ), a diversified medical techn...imaging products and interventional devices dedica...y announced plans to release its,second quarter fi...08 at,8:00 a.m. (eastern). In conjunction with the...n Thursday, May 1, 2008 at 9:00 a.m. (eastern)., ...
...ewswire-FirstCall/ -- China Sky One,Medical, Inc. ...lletin,Board: CSKI), a pharmaceutical company for ...s Republic of China ("PRC"), today announced it,ac...ina Pharmaceutical"), a,recently formed corporatio... 2008., China Sky One Medical, Inc., through its ...
Other Biology Technology:Wyeth Chairman Robert Essner Announces June 27 Retirement 2Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens 2China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc. 2China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc. 3
Mouse Anti-Human LAT, phospho (Tyr226) Monoclonal Antibody, Unconjugated, Clone J96-1238.58.93 from BD Biosciences Pharmingen
TE Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade from Research Organics, Inc.
...t-effective solution to your TechMate Detection re...lity into both our products and service capabiliti... antibodies that have been optimized to the TechMa...iced accessories that can be purchased individuall...
PAP PEN from Invitrogen
Biology Products: